NMN for Hair Growth: Human Study, Hair Loss & Gray Hair Claims

NMN hair growth claims remain preliminary. A small 2025 human study reported hair-quality changes, but there is no controlled evidence that NMN treats androgenetic alopecia, reverses gray hair or produces reliable regrowth.

The 2025 NMN hair study

Fukumoto and colleagues evaluated 15 middle-aged women taking 500 mg/day NMN for 12 weeks. The study reported changes in hair diameter, hair elongation and participants' subjective perception of hair appearance. ^[1]

The result is interesting because it is actual human supplementation data. Its design is also weak for efficacy: without a placebo group, natural hair-cycle variation, grooming changes, expectation effects and measurement variability cannot be separated confidently from the supplement effect.

What the study did not prove

• NMN treats androgenetic alopecia.
• NMN reverses male-pattern baldness.
• NMN reverses female-pattern hair loss.
• NMN treats alopecia areata.
• NMN reverses gray hair.
• 500 mg/day is the optimal hair dose.
• Any commercial NMN brand reproduces the study.

How might NMN affect hair biology?

Hair follicles are metabolically active structures that cycle through growth, regression and rest. NAD-dependent metabolism, mitochondrial function and cellular stress responses are plausible areas of interest, but a plausible follicle mechanism is not equivalent to a proven treatment.

NMN for hair growth vs hair quality

These terms are easy to blur. Increasing shaft diameter or subjective appearance is not the same endpoint as increasing follicle count, reversing miniaturization or treating a diagnosed alopecia. The 2025 study should therefore be described as a preliminary hair-quality intervention rather than a baldness trial.

Does NMN reverse gray hair?

There is no convincing human trial showing oral NMN restores pigment to gray hair. Melanocyte research in skin shows NMN can alter pigmentation pathways in aged melanocytes, but that cannot be transferred directly to hair-follicle repigmentation. ^[2]

How does NMN compare with proven hair-loss treatments?

For androgenetic alopecia, treatments such as minoxidil and—where appropriate—antiandrogen therapies have substantially stronger clinical evidence. NMN should not be positioned as an evidence-equivalent replacement based on a 15-person uncontrolled study.

Would higher NMN doses work better for hair?

No dose-response hair trial exists. The human study used 500 mg/day, but that does not establish that 1,000 mg/day works better or that 250 mg/day would fail.

What should a better NMN hair trial look like?

• Randomized and placebo-controlled.
• Large enough to detect realistic changes.
• Standardized imaging and phototrichogram endpoints.
• Defined hair-loss diagnosis or clearly defined healthy-hair population.
• Objective shaft diameter and density measurements.
• Long enough to span meaningful hair-cycle changes.
• Pre-specified primary endpoint.
• Independent replication.

Hair growth, hair quality and hair loss are different outcomes

A major problem in NMN marketing is that three separate claims are often merged into one. Hair quality can refer to shaft diameter, breakage, texture or subjective appearance. Hair growth can refer to elongation rate or the number of actively growing hairs. Hair-loss treatment usually means preventing follicle miniaturization, increasing terminal-hair density or reversing a diagnosed alopecia.

The 2025 Fukumoto study primarily informs the first two categories. It does not establish the third. ^[3]

What exactly happened in the 2025 human study?

Fifteen middle-aged women took 500 mg/day oral NMN for 12 weeks. Investigators reported improvements in measures including hair diameter and elongation, along with participants' subjective perception of hair appearance. ^[4]

The absence of a placebo group is the central limitation. Hair changes naturally across the anagen, catagen and telogen cycle. Seasonal shedding, styling, hair-care products, diet, illness, hormonal changes and regression to the mean can all create apparent improvement during a 12-week window. A randomized placebo group helps separate those effects from the intervention.

Why a 15-person single-arm study can generate a signal but not a treatment claim

Small exploratory studies are useful for deciding whether a larger trial is worth doing. They are not useless. But they are vulnerable to several forms of bias: there is no blinding, no placebo comparison, subjective outcomes can move with expectation, and a few unusual responders can strongly influence the average.

For hair research, a stronger design would use standardized global photography, phototrichograms, terminal-hair density, shaft diameter and prespecified scalp regions, ideally over at least six to twelve months.

What causes hair loss in the first place?

Hair loss is not one disease. Common explanations include androgenetic alopecia, telogen effluvium after illness or stress, iron deficiency, thyroid disease, rapid weight loss, medication effects, autoimmune alopecia, scalp inflammation and traction. A supplement that hypothetically improves mitochondrial metabolism would not be expected to solve all of these mechanisms.

This is why “does NMN help hair loss?” cannot be answered only by a general statement about NAD+ or aging.

NMN and gray hair: where the claim comes from

Gray hair develops when pigment production in the follicle declines, involving melanocyte stem-cell biology, oxidative stress and age-related changes in the follicular niche. NMN is often inserted into this story because NAD+ participates in cellular stress responses.

We do have a relevant pigmentation paper: NMN reduced melanin production in aged human skin melanocytes and a reconstructed-skin model. ^[5] That result actually demonstrates how dangerous loose extrapolation can be. A change in skin melanogenesis in vitro is not proof of follicular repigmentation, and the direction of the pigmentation effect cannot simply be repurposed as “reverses gray hair.”

What about NMN before-and-after photos?

Before-and-after images are easy to overinterpret. Lighting, hair fibers, styling, angle, hair washing, dye, cut length and camera exposure can change the appearance of density and gray coverage dramatically. Without standardized acquisition and a control group, a photograph is an anecdote rather than an efficacy estimate.

User experiences can still help identify hypotheses or side effects. They should not outrank controlled measurement.

How NMN compares with established hair-loss treatments

Approach	Evidence category	What it addresses
Topical/oral minoxidil	Multiple controlled human trials	Hair density and growth in appropriate alopecia populations
Finasteride/dutasteride where appropriate	Substantial human evidence	Androgen-driven follicle miniaturization
Treating iron/thyroid or other identified cause	Cause-specific medical evidence	Secondary hair loss
NMN	One small uncontrolled hair-quality study	Experimental; not established alopecia therapy

This comparison is not an argument that everyone with hair loss should use a drug. It shows the difference in evidentiary maturity.

Does higher-dose NMN make more sense for hair?

No dose-response hair study exists. The fact that 500 mg/day was used in one experiment does not tell us whether 250 mg would work, whether 1,000 mg would work better, or whether the reported effect would replicate at all. See the NMN dosage evidence map before treating a cosmetic pilot dose as a therapeutic target.

Product quality matters before any hair claim can be tested

Independent studies have found major discrepancies in commercial NMN content and isomer identity. If a product does not contain the stated amount of β-NMN, a personal “hair experiment” cannot even answer whether NMN itself had an effect. See how to verify NMN purity and a COA.

DHT hair-loss models: stronger mechanism, still not human regrowth

A 2024 study tested NMN in a DHT-driven mouse hair-loss model and in human dermal papilla cells exposed to DHT. NMN improved hair-related measures in mice and reduced oxidative/inflammatory stress in the human cells, with changes in androgen receptor, DKK-1, β-catenin and VEGF signaling. ^[6]

This makes androgenetic-alopecia biology more plausible than a generic “NAD is good for cells” argument. But it is still preclinical: no human scalp was randomized to oral NMN versus placebo, and a mouse comparison with minoxidil is not evidence that NMN works as well as minoxidil in people.

What research would change our conclusion?

• A placebo-controlled trial with at least several months of follow-up.
• Separate cohorts for healthy aging hair and diagnosed androgenetic alopecia.
• Objective hair-density, shaft-diameter and growth-rate endpoints.
• Standardized gray-hair counts or pigment measures if repigmentation is claimed.
• Replication by a research group independent of the product manufacturer.
• Dose-response work rather than assuming 500 mg/day is optimal.

Related NMN guides

• NMN and skin
• NMN for women
• NMN benefits
• NMN human evidence

Bottom line

NMN has crossed the line from purely theoretical hair claims to one small human study, but it has not crossed the line to proven hair-loss treatment. The next meaningful step is a randomized placebo-controlled trial with objective hair-density and growth endpoints.